Neurocrine Biosciences Phase 3 KINECT-4 Post Hoc Analysis Demonstrates Clinically Meaningful And Sustained Improvement In Tardive Dyskinesia With Long-Term Use Of INGREZZA Capsules
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences announced positive results from a post hoc analysis of the Phase 3 KINECT-4 study, showing that INGREZZA capsules provide clinically meaningful and sustained improvement in tardive dyskinesia symptoms over 48 weeks.
May 21, 2024 | 8:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences' Phase 3 KINECT-4 study results show that INGREZZA capsules provide sustained improvement in tardive dyskinesia symptoms over 48 weeks, which is likely to positively impact the stock price.
The positive long-term results from the Phase 3 KINECT-4 study for INGREZZA capsules are significant for Neurocrine Biosciences as they demonstrate the drug's efficacy in treating tardive dyskinesia, which is likely to boost investor confidence and positively impact the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100